Heart disease, methamphetamine and AIDS

Area of Science:

• Cardiovascular toxicology
• Immunology
• Neuroscience

Background:

• Methamphetamine (MA) use is associated with significant systemic toxicity beyond its neurological effects.
• Cardiac and immune system dysfunction are critical, yet often under-recognized, consequences of MA abuse.
• Understanding these toxicities is crucial for managing MA users' health.

Purpose of the Study:

• To elucidate the relationship between methamphetamine use and the development of heart disease.
• To detail the immunosuppressive properties of methamphetamine and its impact on immune cell function.
• To examine the compounded risks of MA use in individuals with Human Immunodeficiency Virus (HIV) infection.

Main Methods:

• Review of existing literature on methamphetamine's cardiovascular and immunological effects.
• Analysis of reported cardiovascular manifestations of acute and chronic MA use.
• Examination of studies investigating MA's impact on lymphocyte function and cytokine secretion.

Main Results:

• Acute MA use can lead to tachycardia, arrhythmias, myocardial ischemia, and hypertension.
• Chronic MA use is linked to cardiomyopathy, including cellular infiltration, hypertrophy, rupture, and fibrosis, driven by elevated catecholamines.
• MA disrupts immune function by suppressing lymphocyte responses, reducing lymphocyte counts, and altering T-cell and B-cell cytokine profiles.

Conclusions:

• Methamphetamine use poses a significant threat to cardiovascular health, causing a spectrum of cardiac lesions and cardiomyopathy.
• MA profoundly impacts the immune system, leading to immunosuppression and altered immune cell activity.
• Concomitant MA use and HIV infection exacerbate immunosuppression and increase the risk of cardiac complications, including those related to AIDS and its treatments.